Evidence map›Paper›PMID 29720364›Full record

ArticleJMIR public health and surveillance2018

Monitoring Interest in Herpes Zoster Vaccination: Analysis of Google Search Data.

Elyse J Berlinberg, Michael S Deiner, Travis C Porco, Nisha R Acharya

Open access · goldAbstract read
In one paragraph

Article in JMIR public health and surveillance, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Observational
  8. Article
  9. Estimated Public Health Impact of the Recombinant Zoster Vaccine.Mayo Clinic proceedings. Innovations, quality & outcomes · 2021
    Article
  10. Vaccination for quality of life: herpes-zoster vaccines.Aging clinical and experimental research · 2021
    Review
  11. Article
  12. Observational
  13. Infodemiology and Infoveillance: Scoping Review.Journal of medical Internet research · 2020
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Elyse J BerlinbergFrancis I Proctor Foundation, University of California, San Francisco, San Francisco, CA, United States.ORCID http://orcid.org/0000-0001-5308-1383
Michael S DeinerFrancis I Proctor Foundation, University of California, San Francisco, San Francisco, CA, United States.ORCID http://orcid.org/0000-0002-4977-6147
Travis C PorcoFrancis I Proctor Foundation, University of California, San Francisco, San Francisco, CA, United States.ORCID http://orcid.org/0000-0001-8813-3171
Nisha R AcharyaFrancis I Proctor Foundation, University of California, San Francisco, San Francisco, CA, United States.ORCID http://orcid.org/0000-0002-9762-9475
University of California, San Francisco · US

Funding

Rapid-Prototyping and Design CoreP30EY002162 · NEI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LAKKARAJU, APARNA · 1985 to 2024
$16.8M
The Impact of the Herpes Zoster Vaccine on Herpes Zoster OphthalmicusR01EY028739 · NEI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI NISHA ACHARYA · 2018 to 2026
$4.5M
Digital Detection of Infectious Eye EpidemicsR01EY024608 · NEI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LIETMAN, THOMAS M · 2016 to 2019
$1.5M
NEI NIH HHS P30 EY002162NEI NIH HHS R01 EY024608NEI NIH HHS R01 EY028739
6 · The paper itself

Abstract

backgroundA new recombinant subunit vaccine for herpes zoster (HZ or shingles) was approved by the United States Food and Drug Administration on October 20, 2017 and is expected to replace the previous live attenuated vaccine. There have been low coverage rates with the live attenuated vaccine (Zostavax), ranging from 12-32% of eligible patients receiving the HZ vaccine.

objectiveThis study aimed to provide insight into trends and potential reasons for interest in HZ vaccination.

methodsInternet search data were queried from the Google Health application programming interface from 2004-2017. Seasonality of normalized search volume was analyzed using wavelets and Fisher's g test.

resultsThe search terms "shingles vaccine," "zoster vaccine," and "zostavax" all exhibited significant periodicity in the fall months (P<.001), with sharp increases after recommendations for vaccination by public health-related organizations. Although the terms "shingles blisters," "shingles itch," "shingles rash," "skin rash," and "shingles medicine" exhibited statistically significant periodicities with a seasonal peak in the summer (P<.001), the terms "shingles contagious," "shingles pain," "shingles treatment," and "shingles symptoms" did not reveal an annual trend.

conclusionsThere may be increased interest in HZ vaccination during the fall and after public health organization recommendations are broadcast. This finding points to the possibility that increased awareness of the vaccine through public health announcements could be evaluated as a potential intervention for increasing vaccine coverage.

Indexed as

Google Trendsherpes zosterinfodemiologyInternetperiodicityvaccination

Identifiers

PMID29720364
PMCPMC5956160
OpenAlexW2800817610

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.